- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00028522
R(+)XK469 in Treating Patients With Advanced Neuroblastoma
Phase I Study Of R(+)XK469 In Patients With Advanced Neuroblastoma
연구 개요
상세 설명
OBJECTIVES:
I. Determine the maximum tolerated dose, recommended phase II dose, and dose-limiting toxicity of R(+)XK469 in two different dosing schedules in patients with advanced neuroblastoma.
II. Determine the safety of this drug in these patients. III. Determine the tolerance to this drug in these patients. IV. Determine the pharmacokinetics and pharmacodynamics of this drug and its metabolites in these patients.
V. Determine, preliminarily, any antineoplastic activity of this drug in these patients.
OUTLINE: This is a dose-escalation study.
SCHEDULE A: Patients receive R(+)XK469 intravenously (IV) over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose).
SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Illinois
-
Chicago, Illinois, 미국, 60637-1470
- University of Chicago Comprehensive Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically confirmed high-risk neuroblastoma that has relapsed or is refractory to standard therapy
No active brain metastases
- Previously treated brain metastases allowed if there is no requirement for corticosteroids or anticonvulsants
- Performance status - Karnofsky performance status 70-100% or Lansky score ≥ 70 for your pediatric patients
- More than 3 months
- WBC at least 3,000/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin normal (unless due to documented Gilbert's syndrome)
- Creatinine less than 1.5 times upper limit of normal
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other concurrent uncontrolled illness that would preclude study participation
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study participation
- No prior allergic reaction to compounds of similar chemical or biological composition to study drug (e.g., flurbiprofen or ibuprofen)
- No HIV-positive patients
- No concurrent biologic agents
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
- No other concurrent chemotherapy
- See Disease Characteristics
- At least 4 weeks since prior radiotherapy
- No concurrent palliative radiotherapy
- See Disease Characteristics
- Recovered from all prior therapy
- No other concurrent investigational agents
- No concurrent commercial agents or therapies directed at malignancy
- No concurrent combination anti-retroviral therapy for HIV-positive patients
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Treatment (chemotherapy)
SCHEDULE A: Patients receive R(+)XK469 IV over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose). SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A. |
주어진 IV
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Maximum tolerated dose of XK469 in pediatric patients with advanced neuroblastoma
기간: Day 29 of course 1
|
Defined as the highest dose studied for which the incidence of dose-limiting toxicity (DLT) was less than 33%.
|
Day 29 of course 1
|
DLT
기간: Day 29 of course 1
|
Defined as the occurrence of any of the following: 1) grade 3 or higher nonhematologic toxicity except fatigue, alopecia, nausea, vomiting, 2) grade 4 thrombocytopenia or anemia, 3) any fever accompanied by granulocyte count < 1000/mm^3 (grade 3 or 4 neutropenia), 4) failure to recover absolute neutrophil count 1500/μL
|
Day 29 of course 1
|
Recommended phase II dose
기간: Day 29 of course 1
|
Generally defined as the MTD.
For both schedules A and B and the pediatric dosing schedule, once the recommended phase II dose has been tentatively defined, a total of 12 evaluable patients will be studied to ensure the feasibility of this dose for phase II trials.
If interindividual pharmacokinetic variability is high, additional patients will be enrolled (maximum of 20 at the phase II dose) to permit adequate pharmacological characterization of XK469 and the relationship of interindividual pharmacokinetic variability to toxicity.
|
Day 29 of course 1
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Metabolism of XK469 in pediatric patients
기간: Days 1-3 of course 1
|
Performed by high-performance liquid chromatography (HPLC).
Plasma metabolic ratios between metabolite and XK469 concentrations will be used as an index of metabolic activity and phenotype for each patient.
The modality of the frequency distribution of metabolic ratios will be also described.
|
Days 1-3 of course 1
|
Pharmacokinetics of XK469 in pediatric patients
기간: Days 1-3 of course 1
|
The maximum number of samples for pharmacokinetic studies will not exceed 20.
Analyzed by non compartmental method using the WinNonlin software.
Parameters include the elimination rate constant, the area under the concentration vs. time curve (AUC), terminal half-life, total (nonrenal + renal) clearance, and volume of distribution at steady state.
Mean, standard deviation, and coefficient of variation will be determined for each parameter.
|
Days 1-3 of course 1
|
Pharmacodynamics of XK469 in pediatric patients
기간: Continuously over the course of study treatment
|
Performed by correlating area under the curve (AUC) (and other parameters) of R(+)XK469 and metabolites with observed toxicities.
Specifically, we will compare the AUC in those patients who experience grade >= 2 toxicity to those who experience grade < 2 toxicity using a Wilcoxon, nonparametric rank-sum test.
|
Continuously over the course of study treatment
|
Antineoplastic activity of XK469 for neuroblastoma
기간: Every 2 courses
|
Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.
|
Every 2 courses
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Susan Cohn, University of Chicago Comprehensive Cancer Center
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NCI-2009-00013 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- U01CA069852 (미국 NIH 보조금/계약)
- UCCRC-11108B
- CDR0000739128
- NCI-4570
- 11108B (기타 식별자: University of Chicago Comprehensive Cancer Center)
- 4570 (기타 식별자: CTEP)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
R(+)XK469에 대한 임상 시험
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)완전한
-
National Cancer Institute (NCI)완전한만성골수단구성백혈병 | 재발성 성인 급성 골수성 백혈병 | 성인 급성 거핵모구성 백혈병(M7) | 성인 급성 최소 분화 골수성 백혈병(M0) | 성인 급성 단일모구성 백혈병(M5a) | 성인 급성 단핵구 백혈병(M5b) | 성숙을 동반한 성인 급성 골수성 백혈병(M2) | 성숙하지 않은 성인 급성 골수성 백혈병(M1) | 11q23(MLL) 이상이 있는 성인 급성 골수성 백혈병 | Inv(16)(p13;q22)가 있는 성인 급성 골수성 백혈병 | T(16;16)(p13;q22)를 동반한 성인 급성 골수성 백혈병 | T(8;21)(q22;q22)를 동반한 성인 급성 골수성... 그리고 다른 조건미국
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)완전한
-
Daping Hospital and the Research Institute of Surgery...아직 모집하지 않음
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)아직 모집하지 않음